Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 5,936 matching trials from the live ClinicalTrials.gov search.
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Testosterone Undecanoate

NCT01765179
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 2Phase 3 Interventional Results available

Oral Naltrexone In Pediatric Eating Disorders

NCT05073679
Conditions
Anorexia Nervosa/Bulimia, Anorexia in Adolescence, Anorexia Nervosa, Atypical, Anorexia Nervosa, Binge Eating/Purging Type, Purging (Eating Disorders), Impulsive Behavior, Eating Disorders, Bulimia Nervosa, Eating Disorders in Adolescence
Interventions
Naltrexone Hydrochloride, Control
Drug · Other
Lead sponsor
Rosemary Claire Roden
Other
Eligibility
13 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
HER-2 Positive Breast Cancer, Metastatic Breast Cancer
Interventions
IV LBH589, Oral LBH589, trastuzumab, paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Mobile, Alabama
Conditions
Atrial Fibrillation or Flutter
Interventions
Vanoxerine HCl, Placebo
Drug
Lead sponsor
Laguna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more
Conditions
Crohn's Disease
Interventions
STA-5326 mesylate
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Iressa Study in Patients With Salivary Gland Cancer

NCT00509002
Conditions
Salivary Gland Cancer
Interventions
Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Conditions
Parkinson's Disease (PD)
Interventions
Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Port Charlotte, Florida • Round Rock, Texas
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
221,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Studying Different Formulations of SR13668 in Healthy Volunteers

NCT00896207
Conditions
Healthy, no Evidence of Disease
Interventions
Akt inhibitor SR13668
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 62 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years · Male only
Enrollment
8,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
297
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Oral MG001

NCT07204171
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
mitragynine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Solid Tumor, Metastatic Bladder Cancer
Interventions
RX-3117
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed No phase listed Observational Accepts healthy volunteers

Fasting Predictors of OGTT and MMTT Response

NCT01998867
Conditions
Prediabetes, Hypertension, Obesity, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Health Diagnostic Laboratory, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Patients With Advanced Solid Tumor or Lymphoma
Interventions
APG-115
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions
oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
La Jolla, California • Denver, Colorado • Las Vegas, Nevada + 5 more
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

NCT00479219
Conditions
Alzheimer Disease
Interventions
GSI-953, Placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Glendale, California
Conditions
Obesity, Overweight
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Kissimmee, Florida + 10 more
Conditions
Alzheimer Disease
Interventions
Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Food Allergy
Interventions
Omalizumab
Biological
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
6 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Coral Gables, Florida
Conditions
Gingival Recession
Interventions
enamel matrix derivative, Porcine collagen matrix
Biological · Device
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland